|
AMPHOTERICIN B |
| (1R-(1R',3S',5R',6R',9R',11R',15S',16R',17R',18S',19E,21E,23E,25E,27E,29E,31E,33R', 35S',36R',37S'))-33-(( 3-Amino-3,6-dideoxy-beta-D- mannopyranosyl)oxy)-1,3,5,6,9,11,17,37- octahydroxy-15,16,1 8-trimethyl-13-oxo-14,39-dioxabicyclo(33.3.1) nonatriaconta- 19,21,23,25,27,29,31-heptaene- 36-carboxylic acid; Abelcet; Abelecet; AmBisome; Amfotericina B; Amfotericina B; Ampho-Moronal; Amphocin; Amphotec; Amphotericin B; Amphotericine B; Amphotericine B; Amphotericinum B; Amphotericinum B; Amphozone; Fungilin; Fungizone; Mysteclin-F; Tegope; Other RN: 30782-62-8, 54482-28-9, 8055-20-7 |
|
|
| PRODUCT IDENTIFICATION |
|
|
CAS RN |
1397-89-3 |
|
EINECS RN |
215-742-2 |
|
FORMULA |
C47H73NO17 |
|
MOLE WEIGHT |
924.08 |
|
H.S.CODE |
2941.90.1010 |
|
CLASSIFICATION |
Amebicide, Antibacterial, Anti-Infective, Antifungal, Antiparasitic, Antiprotozoal |
|
EXTRA NOTES |
Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela. |
|
|
| PHYSICAL AND CHEMICAL PROPERTIES |
|
|
PHYSICAL STATE |
white to off-white powder |
|
MELTING POINT |
|
|
BOILING POINT |
|
|
DENSITY |
|
|
SOLUBILITY IN WATER |
Insoluble (soluble in DMF, DMSO) |
|
pH |
|
|
VAPOR DENSITY |
|
|
REFRACTIVE INDEX |
|
|
FLASH POINT |
|
|
|
| STABILITY AND REACTIVITY | |
| STABILITY | Stable under normal conditions. |
|
INCOMPATIBLE MATERIALS |
Strong oxidizing agents |
| DECOMPOSITION PRODUCTS |
Carbon oxides, nitrogen oxides |
| POLYMERIZATION | Has not been reported |
|
NFPA RATINGS |
Health:2 , Flammability:0 , Reactivity:0 |
|
|
| SAFETY |
|
|
HAZARD NOTES |
Target Organ Effect (Kidney). Irritant. Prolonged or repeated exposure may cause allergic reactions in certain sensitive individuals. |
|
EYE |
Cause eye irritation. |
|
SKIN |
May be harmful if absorbed through skin. Cause skin irritation. |
|
INGESTION |
May be harmful if swallowed. |
|
INHALATION |
May be harmful if inhaled. Cause respiratory tract irritation. |
|
CHRONIC |
|
|
|
| TRANSPORT & REGULATORY INFORMATION |
|
|
UN NO. |
|
| HAZARD CLASS |
|
| PACKING GROUP |
|
| HAZARD SYMBOL |
XI |
|
RISK PHRASES |
36/37/38 |
|
SAFETY PHRASES |
26-36 |
|
|
| EXTERNAL LINKS & GENERAL INFORMATION | ||||||||||||||||||||||
|
Amphotericin B is an amphoteric polyene macrolide antibiotic produced by Streptomyces nodosus. Amphotericin B, formulated with sodium deoxycholate, was the first parenteral amphotericin B preparation available commercially. Because amphotericin B deoxycholate is associated with certain dose-limiting toxicities (principally nephrotoxicity), other parenteral amphotericin B preparations have been developed with lipid-based drug delivery systems. Amphotericin B is now commercially available as amphotericin B cholestryl sulfate complex (Amphotec), amphotericin B lipid complex (Abelcet), and amphotericin B liposomal (AmBisome). (http://aidsinfo.nih.gov/) Amphotericin B is a polyene antifungal derived from Streptomyces nodosum. It has been widely used to treat aspergillosis, candidiasis, coccidioidomycosis and cryptococcosis since it was first isolated in 1953. It works by binding to a sterol moiety on the surface of the organism, causing cell death by increasing cell membrane permeability. The clinical response does not always correlate with the result of in vitro testing. Consider combined treatment with flucytosine (q.v.) when managing systemic fungal infection because amphotericin only penetrates the CSF poorly. Fluconazole (q.v.) on its own may come to be accepted as the treatment of choice for systemic Candida albicans infection. Caspofungin (see web commentary) may be tried if systemic infection with a Candida organism fails to respond to amphotericin. (http://www.blackwellpublishing.com/) Pharmacological Actions
|
||||||||||||||||||||||
|
|
| SALES SPECIFICATION |
|
|
APPEARANCE |
white to off-white powder |
|
ASSAY |
750µg/mg min |
|
LOSS ON DRYING |
5.0% max |
| RESIDUE ON IGNITION |
1.5% max |
| AMPHOTERICIN A |
15.0% min |
|
|
| PACKING |
|
|
|
|
| PRICE INFORMATION |
|
|